DDInter419 DDInter1657
Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine receptors results in fewer extrapyramidal side effects, especially tardive dyskinesia. However, its promiscuity toward the muscarinic and adrenergic receptors can result in other side effects, notably gastrointestinal hypomotility and orthostatic hypotension. [L905,A215552]. Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine was briefly removed from the market in various jurisdictions in 1970 due to severe agranulocytosis.[A256713,A256718] However, continued evidence of its effectiveness led to clozapine's eventual reintroduction, although
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells.[L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant. Other chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant. Selinexor was also granted accelerated approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have gone through at least 2 lines of systemic therapy. The FDA approved Selinexor in June 2019. The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.
Clozapine {u} (Compound) resembles {v} (Compound) Trifluoperazine
Clozapine {u} (Compound) resembles {v} (Compound) Prochlorperazine
Clozapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azatadine
Clozapine {u} (Compound) binds {v} (Gene) CYP2D6
Clozapine {u} (Compound) upregulates {v} (Gene) ST3GAL5
Clozapine {u} (Compound) palliates {v} (Disease) bipolar disorder
Clozapine {u} (Compound) downregulates {v} (Gene) POLR2I
Clozapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Clozapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Caffeine
Clozapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trospium
Clozapine (Compound) resembles Trifluoperazine (Compound)
Clozapine (Compound) resembles Prochlorperazine (Compound)
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Clozapine (Compound) binds CYP2D6 (Gene)
Clozapine (Compound) upregulates ST3GAL5 (Gene)
Clozapine (Compound) palliates bipolar disorder (Disease)
Clozapine (Compound) downregulates POLR2I (Gene)
Clozapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Clozapine may cause a minor interaction that can limit clinical effects when taken with Caffeine
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Trospium